ARL6IP1P1

Across TCGA pan-cancer cohorts, ARL6IP1P1 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of ARL6IP1P1’s most consistent transcriptional readouts.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where ARL6IP1P1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ARL6IP1P1 is over-expressed in tumor.

PRAD are the cancer types where ARL6IP1P1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARL6IP1P1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PRAD	All	All	+0.017	.007	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 1 strongest of 1 lineages.

ARL6IP1P1–PRAD

Open the PRAD breakdown →